Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Bristol-Myers Squibb0 个研究点目标入组 1,144 人开始时间: 2009年1月最近更新: 2016年9月20日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 1,144
主要终点: Annualized total and per patient cost of patients diagnosed with NVAF or VTE treated with VKA and according to coagulation control status based on electronic clinical records

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTR≥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients aged 18 or older over the study period
•Patients with a diagnosis for NVAF or VTE anytime in their medical records
•Patients having at least one year of enrolment in the database prior to the index date
•Patients newly initiated with VKA during the study period (index date)

排除标准

•Patients with a diagnosis for both NVAF and VTE anytime in their medical records

结局指标

主要结局

Annualized total and per patient cost of patients diagnosed with NVAF or VTE treated with VKA and according to coagulation control status based on electronic clinical records

时间窗: Approximately 60 months

Per patient cost: direct medical costs from hospitalizations, consultations, medications, and tests; Coagulation control status: adequately controlled patients defined by INR between 2-3 and TTR≥ 60%

次要结局

Demographic and clinical characteristics for all patients diagnosed with NVAF or VTE treated with VKA and according to coagulation control status based on electronic clinical records(Approximately 60 months)
Healthcare resource rates for all patients diagnosed with NVAF or VTE treated with VKA and according to coagulation control status based on electronic clinical records(Approximately 60 months)

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Estimation of cost value for health care professionals based on the convenience of anti-influenza agent baloxavir marboxilinfluenza

JPRN-UMIN000042606Shionogi & Co., Ltd.2,750

已完成

不适用

Economic Evaluation in Cardiology: Remote Monitoring of PacemakersCardiovascular Disease

NCT02234245Universidad de Almeria83

已完成

不适用

Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional TherapyArthritis, Psoriatic, Psoriasis

NCT00303186Pfizer107

已完成

不适用

Health-economic Evaulation of Interventional Pain MangementChronic Pain

NCT01835704Eques Indolor AB1,540

已完成

不适用

Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative DatabasesMultiple Chronic Illnesses

NCT01761253Weill Medical College of Cornell University241,000